10-K · March 13, 2026
SenesTech reported full-year 2025 revenue of $2.221 million, up 20% from $1.857 million in 2024, driven by Evolve product growth. Gross margin improved to 62.5% in 2025, but the company remains unprofitable with a 2025…
Earnings analysis · 10-Q
SNES earnings analysis
Filed May 12, 2026 · Our reading of the company's report
The latest report
SenesTech, Inc. reported Q1 2026 revenue of $493,000, a 2% increase from $485,000 in Q1 2025, but below estimates of $631,600. The company recorded a diluted EPS of -$0.39 compared to an expected -$0.33. Key drivers…
Read full summary
SenesTech, Inc. reported Q1 2026 revenue of $493,000, a 2% increase from $485,000 in Q1 2025, but below estimates of $631,600. The company recorded a diluted EPS of -$0.39 compared to an expected -$0.33. Key drivers included an 85% contribution from the Evolve product line, which indicates strong market performance despite overall financial losses and increased operating expenses.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.39
- Gross margin
- 68.6%
What stood out
-
Revenue Growth
Q1 2026 revenue reached $493,000, up 2% from $485,000 in Q1 2025.
-
Strong Evolve Revenue Contribution
Evolve product line accounted for 85% of total revenue in Q1 2026, up from 79% in the prior year.
-
Improved Gross Margin
Gross margin improved to 68.6% in Q1 2026 from 64.5% in Q1 2025 due to increased efficiency.
-
Interest Income Increase
Net interest income rose to $56,000 from a net expense of $2,000 a year ago.
-
Cash Position
Cash and cash equivalents were $6.8 million as of March 31, 2026, down from $8.6 million at year-end 2025.
-
Controlled Inventory Costs
Cost of sales declined to $155,000, or 31.4% of net sales, from $172,000, or 35.5% last year.
What to watch
-
Increased Net Loss
Net loss for Q1 2026 was $2.1 million, a 24% increase compared to a net loss of $1.7 million in Q1 2025.
-
Rising Operating Expenses
Total operating expenses surged 24% to $2.5 million in Q1 2026 from $2.0 million in Q1 2025.
-
Potential Need for Additional Financing
Management stated the need for potential additional financing if revenue growth does not meet expectations.
Management's outlook
Management anticipates Q2 2026 revenue to range between $450,000 and $550,000.
Earlier filings 4
10-Q · November 10, 2025
SenesTech reported Q3 2025 revenue of $690 (in thousands), up from $482 in Q3 2024, with gross profit of $433 and EPS (loss per share) improving to $(0.28). Liquidity materially strengthened following equity and warrant…
10-K · February 21, 2024
SenesTech is focused on commercializing two pest-fertility products, ContraPest (EPA-registered and cleared in all 50 states, DC and five U.S. territories) and Evolve (launched November 2023 and authorized in 30…
10-Q · November 9, 2023
SenesTech reported Q3 2023 revenue of $360 (in thousands), up from $250 (in thousands) in Q3 2022, with gross profit of $176 (in thousands). The company narrowed its quarterly net loss to $(1,947) (in thousands) (EPS…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.